50
Participants
Start Date
September 4, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
April 1, 2026
glucose, insulin, and potassium (GIK)
"GIK formulation: 100 g/L glucose, 33 U/L insulin, and 40 mmol/L KCl~Reference PMID: 32151220. Formulation represents a 50% reduction in compounded solute combination from the reference study, which allows for administration via peripheral IV."
Crystalloid Infusion
placebo
University of Washington Medical Center, Seattle
University of Washington
OTHER